Findings

What do systematic reviews say?

12 questions · 12 findings · 3 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 16.7%Very low 3 · 25%Low 6 · 50%Moderate 1 · 8.3%High 0 · 0%

Antidepressants vs opioid antagonists

Depressive symptoms · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 62 participants
Very low

Antidepressants vs mood stabilisers

Depressive symptoms · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Very low

Antidepressants vs placebo

Depressive symptoms · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 90 participants
Low

Discontinuation with high‐intensity psychological interventions vs continuation

Depressive symptoms · participants with long‐term antidepressants for depressive disorders

1 finding from 1 review

Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety… 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 484 participants
Low

Discontinuation of long‐term antidepressant with minimal intervention vs usual care

Depressive symptoms · participants with long‐term antidepressants for depressive or anxiety disorders

1 finding from 1 review

Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Low

Abrupt discontinuation vs continuation of long‐term antidepressants

Depressive symptoms · participants with depressive or anxiety disorders

1 finding from 1 review

Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety… 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 330 participants
Very low

Paroxetine vs doxepin

> 50% reduction in depressive symptoms · people with epilepsy and depression

Paroxetine showed no clear difference in > 50% reduction in depressive symptoms compared with doxepin (moderate certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 1.16 [0.88, 1.52]
1 study · 67 participants
Moderate

Venlafaxine vs no treatment

> 50% reduction in depressive symptoms · people with epilepsy and depression

Venlafaxine may leads to higher > 50% reduction in depressive symptoms compared with no treatment (low certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 3.25 [1.19, 8.9]
1 study · 64 participants
Low

Sertraline vs cognitive behavioural therapy

> 50% reduction in depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

> 50% reduction in depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
45 participants
Low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

> 50% reduction in depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Amitriptyline vs nomifensine

> 50% reduction in depressive symptoms · people with epilepsy and depression

Amitriptyline showed no clear difference in > 50% reduction in depressive symptoms compared with nomifensine (low certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 0.55 [0.28, 1.06]
1 study · 28 participants
Low